Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The wild-type (wt) p53 protein has transcriptional activation functions which may be linked to its tumor suppressor activity. Many mutant p53 proteins expressed in cancers have lost the ability to function as transcriptional activators and furthermore may inhibit wt p53 function. To study the mechanisms by which mutant forms of p53 have lost their transactivation function and can act in a dominant negative manner, a structure-function analysis of both mutant and engineered truncated forms of p53 was carried out. We show that different mutant p53 proteins found in cancers vary in the ability to inhibit the transcriptional transactivation and specific DNA binding activities of wt human p53. This transdominant effect was mediated through the carboxy-terminal oligomerization region. The role of the transactivation activity in transformation suppression by wt p53 was also examined by constructing an N-terminal deletion mutant lacking the transactivation domain. This mutant was unable to transactivate but could bind specifically to DNA. Although it was impaired in its ability to suppress transformation of primary rat embryo fibroblasts by adenovirus E1A plus activated ras, the N-terminal deletion mutant still had some suppression activity, suggesting that additional functions of p53 may contribute to transformation suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
Regulation of the Human hsp70 Promoter by p53
Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993) · Science · doi:10.1126/science.8418500 · Cited by 292
Cited by
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release
Schuler, M., Bossy-Wetzel, E., Goldstein, J. C., Fitzgerald, P., & Green, D. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7337 · Cited by 560
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
Identification of a novel p53 functional domain that is necessary for efficient growth suppression
Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 471
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Sequence-specific transcriptional activation is essential for growth suppression by p53.
Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., & Vogelstein, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.1998 · Cited by 406
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
Unger, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1805 · Cited by 367
Self-citationThe MDM2 RING-finger domain is required to promote p53 nuclear export
Geyer, R. K., Yu, Z. K., & Maki, C. G. (2000) · Nature Cell Biology · doi:10.1038/35023507 · Cited by 361
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00418.x · Cited by 301
A DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1
Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., & Lu, H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00176-9 · Cited by 299
Buschmann, T., Potapova, O., Bar-Shira, A., Ivanov, V. N., Fuchs, S. Y., Henderson, S., Fried, V. A., Minamoto, T., Alarcon-Vargas, D., Pincus, M. R., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2743-2754.2001 · Cited by 289
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
Cell cycle control, checkpoint mechanisms, and genotoxic stress.
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s15 · Cited by 257
Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2
Ferreon, J. C., Lee, C. W., Arai, M., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811023106 · Cited by 210
Shin, T. H., Paterson, A. J., & Kudlow, J. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4694 · Cited by 78
p53 is an important regulator of CCL2 gene expression
Tang, X., Asano, M., O’Reilly, A., Farquhar, A., Yang, Y., & Amar, S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480844 · Cited by 30
Metadata
- Authors
- Unger, T., Mietz, J. A., Scheffner, M., Yee, C. L., & Howley, P. M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1993-09
- Volume
- 13
- Issue
- 9
- Pages
- 5186-5194
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1767560565
- Cited by
- 123
- References
- 11
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.